All About SGLT Inhibitors for T1D

SGLT inhibitors are oral medications that work by decreasing the production of transport proteins and reducing the absorption of glucose by the intestines and kidneys respectively. Up until now, these drugs have been used exclusively by those with Type 2 diabetes. Inhibitors on the market currently include SGLT-2 inhibitors Farxiga and Jardiance, and Zynquista, the first dual SGLT-1 and SGLT-2 inhibitor.

First Oral Medication to Treat T1D Approved in Europe

The European Commission (EC) has approved the use of Forxiga (dapagliflozin) as an add-on treatment to insulin therapy for use in in patients with T1D who have a BMI ≥ 27 kg/m2

FDA Declines to Approve First Oral Medication for Type 1 Diabetes

The FDA issued a Complete Response Letter for the SGLT-1/2 inhibitor Zynquista (sotagliflozin), declining to approve it for use in T1D at this time.

Senseonics Appoints Francine R. Kaufman, M.D. as Chief Medical Officer

Francine R. Kaufman, M.D., a member of Beyond Type 1’s Science Advisory Council, was appointed Chief Medical Officer at Senseonics.

Making An Invisible Disease Visible: Injecting Myself On Adventure Cyclist Magazine

Annalisa van den Bergh injects herself on the cover of Adventure Cycling, the largest cycling magazine.

Insulin Manufacturers Called on to Explain Skyrocketing Prices

On Tuesday, a group of U.S. Senators led by Patty Murray (D-WA) sent letters to executives at Eli Lilly, Novo Nordisk, and Sanofi demanding information about the rising prices of insulin.  

UCSF Team First to Grow Insulin-Producing Cells from Human Stem Cells

Researchers at UCSF have created insulin-producing cells from human stem cells, an incredible breakthrough and benchmark on the road to curing Type 1 diabetes. This is the first time scientists have been able to achieve this feat of regenerative medicine.

UnitedHealthcare Decision — A Step Backwards for Pump Access

UnitedHealthcare's announcement of a preferred insulin pump for pediatric patients has been denounced by Beyond Type 1 and JDRF.

The Future of Glucagon with Xeris CEO Paul Edick

Beyond Type 1 talks to Paul Edick, President and CEO of Xeris Pharmaceuticals, about their revolutionary glucagon pen.

Government Shutdown Leads to Insulin Rationing

Government workers are increasingly unable to afford basic necessities like food, power, and critical medications like insulin.

Congressman Introduces “Insulin Access For All Act” for Medicaid and Medicare Beneficiaries

Representative Bobby Rush (D-Ill) introduced the Insulin Access For All Act to eliminate the cost-sharing requirement for patients on Medicare and Medicaid

FDA Advisory Vote Split 8-8 on SGLT Inhibitor for T1D

Votes on Zynquista from panel members on the Endocrinologic and Metabolic Drugs Advisory Committee were split 8 to 8. This was the first ever regulatory review for an SGLT inhibitor for use in Type 1 diabetes in the United States.

National Health Services to Provide Free CGMs to Pregnant Women with T1D in UK

National Health Services England announced Monday that it would offer continuous glucose monitors to all pregnant women with T1D by 2021.

CW Star Unveils Teen Superheroes with Disabilities

Austin Basis details his comic book series "The Kinetix," which features a protagonist who fights crime while maintaining his Type 1 diabetes.

Research Team Delays Onset of Type 1 Diabetes in Mice

Dr. Massimo Pietropaolo and his team of experimenters at Baylor College of Medicine and the University of Michigan Medical School have determined that certain B cells may have the capacity to delay the onset of T1D.